セミナー開催のご案内

Symposium 212

IBD and Liver: East Meets West 2018年9月7-8日 京都ホテルオークラIBD and Liver: East Meets West 2018年9月7-8日 京都ホテルオークラ

  • ごあいさつごあいさつ
  • プログラムプログラム
  • アクセス・お問い合わせアクセス・お問い合わせ
  • ポスター募集ポスター募集
  • 参加登録参加登録

プログラムプログラム

Friday, September 7, 2018

  • 8.30
    Welcome
    T. Hibi,Tokyo
  • 8.40

    State-of-the-Art Lecture:
    Regeneration of intestinal epithelial cells and IBD

    M. Watanabe,Tokyo
Session I
Optimization of clinical practice in IBD:
What can we learn from differences
between Asian and Western countries?
Chair:S. Schreiber, Kiel; Y. Suzuki, Chiba
  • 9.20
    Epidemiology - Trends in IBD in Asia
    S.C. Ng,Hong Kong
  • 9.40
    The best way of using anti-TNF and immunomodulators considering the Asian-specific situation
    T. Matsumoto,Iwate
  • 10.00
    New strategy in the surveillance colonoscopy for colitis associated colorectal cancer
    T. Watanabe,Tokyo
  • 10.20
    Fecal biomarkers, potential and limitations
    M. Allez,Paris
  • 10.40

    Coffee break with poster session

Session II
Personalized health care in special situations in IBD
Chair:A. Hart, Harrow; K. Okazaki, Osaka
  • 11.10
    Very early onset IBD
    R.J. Xavier,Boston
  • 11.30
    IBD in elderly patients
    C.N. Bernstein,Winnipeg
  • 11.50
    IBD and pregnancy
    U. Mahadevan,
    San Francisco
  • 12.10
    Gender issues
    A. Hart,Harrow
  • 12.30

    Lunch break with poster session

Session III
Optimization of IBD treatment
Chair:G. D’Haens, Amsterdam; H. Nakase, Sapporo
  • 14.00
    Predictors of low adherence to therapy in patients with IBD
    C. Selinger,Leeds
  • 14.20
    Risk management in thiopurine therapy
    F. Hoentjen,Nijmegen
  • 14.40
    Therapeutic drug monitoring (TDM): Its role in anti TNF therapy
    M. Ferrante,Leuven
  • 15.00
    Postoperative management of Crohn‘s disease patients
    D. Sorrentino,Roanoke
  • 15.20

    Coffee break with poster session

Session IV
Mechanism-based treatment strategy for IBD:
How to use new medicines properly
Chair:T. Hisamatsu, Tokyo; G. Rogler, Zurich
  • 15.50
    IBD pathogenesis and novel therapeutic targets
    G. Rogler,Zurich
  • 16.10
    Anti-TNF strategies and cytokine inhibitors
    M.F. Neurath,Erlangen
  • 16.30
    Inhibitors of cellular adhesion molecules and leukocyte trafficking
    S. Danese,Milan
  • 16.50
    JAK inhibitors
    T. Kobayashi,Tokyo
  • 17.10
    Summary of the day
    E.M. El-Omar,Sydney
  • 17.25

    Scientific discussion with snacks

Saturday, September 8, 2018

Session V
Gut flora and metabolism in human health care and diseases
Chair:A. Andoh, Shiga; M.F. Neurath, Erlangen
  • 8.30
    The impact of intestinal epithelial barrier function
    K. Takeda,Osaka
  • 8.50
    Impact of gut luminal metabolism in human health care
    S. Fukuda,Yamagata
  • 9.10
    The role of the microbiota in immune homeostasis and disease
    H. Ohno,Kanagawa
  • 9.30
    The role of diet and gut microbiota in health and metabolic diseases
    E.B. Chang,Chicago
  • 9.50
    Gut microbiota and hepatic carcinogenesis
    E. Hara,Osaka
  • 10.10

    Coffee break with poster session

Session VI
NAFLD
Chair:T. Okanoue, Osaka; H. Tilg, Innsbruck
  • 10.40
    Pathogenesis of NAFLD
    H. Tilg,Innsbruck
  • 11.00
    Role of the microbiome in the pathogenesis of NAFLD
    A. Nakajima,Kanagawa
  • 11.20
    Non-invasive diagnostic approaches for NAFLD
    R. Loomba,La Jolla
  • 11.40
    Current and future treatment of NAFLD
    Z.M. Younossi,Falls Church
  • 12.00
    Presentation of Poster Awards
    T. Hisamatsu,Tokyo
  • 12.15

    Lunch break with poster session

Session VII
Viral hepatitis
Chair:K. Koike, Tokyo; J.-M. Pawlotsky, Paris
  • 13.30
    Innate and adaptive immune response in viral hepatitis
    T. Kanto,Chiba
  • 13.50
    Current treatment of hepatitis B
    H. Lik Yuen Chan,
    Hong Kong
  • 14.10
    Hepatitis C therapy: Everything solved?
    J.-M. Pawlotsky,Paris
  • 14.30
    Hepatitis E: The new epidemic?
    H. Okamoto,Tochigi
  • 14.50

    Coffee break with poster session

Session VIII
Autoimmune liver diseases
Chair:T.H. Karlsen, Oslo; H. Takikawa, Tokyo
  • 15.20
    Clinical management of PBC
    Y. Ueno,Yamagata
  • 15.40
    The many faces of AIH
    A. Tanaka,Tokyo
  • 16.00
    PSC: From genes to therapy
    T.H. Karlsen,Oslo
  • 16.20
    IgG4-related sclerosing cholangitis
    H. Hamano,Nagano
  • 16.40
    Closing remarks
    M. Imawari,Kanagawa